ZenithBIO Successes Highlight Flexibility, Network & Breadth of Industry
For a Specialty Pharma Client: Against the odds: Identified a viable P-3 clinical asset.
For a private biotech Client:
Conducted in-depth KOL & clinician interviews that identified critical commercial end points for their clinical
For a Drug Delivery Client: Pipeline analyses combining KOL interviews with market data increased valuation
during M&A negotiations.
For Virtual Companies: Seamless interaction with other external consulting groups across the biopharma
functional & commercial areas.
Therapeutic Areas: Broad Experience Across Specialty & Primary Care Conditions
AutoImmune & Inflammatory
Cardiology: Acute & Chronic
Success stories after-the-fact look easy, but
the challenge is understanding the strategic potential of opportunities as well as the risks early on, in order to optimize
the value of deals, pipelines, and product launches.